1. Давыдов М.И. Энциклопедия клинической онкологии. М.: ООО "РЛС2004"; 2004.

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Cancer of the Nasopharynx. Version 2.2023.

3. Гурцевич В.Э., Сенюта Н.Б., Кондратова В.Н., Гончарова Е.В., Игнатова А.В., Ломая М.В., Кропотов М.А., Мудунов А.М., Лихтенштейн А.В. Диагностическая значимость уровней ДНК и антител к капсидному антигену вируса Эпштейна-Барр в плазме крови больных раком носоглотки в неэндемическом регионе. Успехи молекулярной онкологии 2015; 2(2): 56 - 62.

4. Каприн А.Д. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность)/А.Д. Каприн [и др]. - 2024: ФГБУ "МНИОИ им П.А. Герцена" Минздрава России, 2024.

5. Международная классификация болезней - онкология (МКБ-О), 3 издание, 1 пересмотр. Сост. Э. Фритц, К. Перси, Э. Джек, К. Шанмугаратнам, Л. Собин, Д.М. Паркин, Ш. Уилан/Пер. с англ. А.В. Филочкиной, под ред. А.М. Беляева, О.Ф. Чепика, А.С. Артемьевой, А.А. Барчука, Ю.И. Комарова - СПб.: Издательство "Вопросы онкологии", 2017. - 352 с.

6. Dogan S., Hedberg M.L., Ferris R.L. et al. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2014; 36: 511 - 516.

7. Zhang W., Chen Y., Chen L. et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015; 94: e845.

8. Lin J.C., Wang W.Y., Chen K.Y. et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461 - 2470.

9. Lin J.C., Wang W.Y., Liang W.M. et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative; PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1342 - 1348.

10. Prayongrat A., Chakkabat C., Kannarunimit D. et al. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res 2017; 58: 509 - 516.

11. Leung S.F., Chan A.T., Zee B. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288 - 291

12. Leung S.F., Chan K.C., Ma B.B. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25: 1204 - 1208.

13. Gulley M.L. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001; 3: 1 - 10.

14. Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A, Machiels JP; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; EURACAN. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and . Ann Oncol. 2021 Apr; 32(4): 452 - 465. doi: 10.1016/j.annonc.2020.12.007.

15. ESMO NPC: The best imaging for detecting distant metastases is FDG-PET in terms of sensitivity and specificity, and it is recommended at least in locally advanced disease.

16. Bossi P., Chan A.T.C., Licitra L., et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of Oncology. 2021. Vol. 32, no. 4. P. 452 - 465.

17. Hung GU, Wu IS, Lee HS, You WC, Chen HC, Chen MK. Primary tumor volume measured by FDG PET and CT in nasopharyngeal carcinoma. Clin Nucl Med 2011; 36: 447 - 451.

18. J.-P. Machiels, C. Rene Leemans, W. Golusinski, C. Grau, L. Licitra & V. Gregoire, on behalf of the EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board/Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. - Annals of oncology - Oct. 2020.

19. ESMO NPC: PET imaging may be used in cases of equivocal imaging results. Sensitivity of MRI and PET are similar, whereas the specificity of PET is higher and so helps to differentiate between post-irradiation changes and recurrent tumours.

20. Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J., PET-NECK Trial Management Group. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med. 2016 Apr 14; 374(15): 1444 - 54.

21. Blanchard P., Lee A., Marguet S. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015; 16: 645 - 655.

22. Zhang Y., Li W.F., Liu X. et al. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. Radiother Oncol 2017.

23. Ribassin-Majed L., Marguet S., Lee A.W. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2016: Jco2016674119.

24. Jin Y., Cai X.Y., Shi Y.X. et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012 Oct; 138(10): 1717 - 25.

25. Zhang L., Huang Y., Hong S. et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388: 1883 - 1892.

26. Ward MC, Riaz N, Caudell JJ, et al. Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: A multi-institution cohort study by the MIRI Collaborative. Int J Radiat Oncol 2018; 100: 586 - 594.

27. Boero IJ, Paravati AJ, Xu B, Cohen EE, Mell LK, Le QT, Murphy JD. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 1; 34(7): 684 - 90. doi: 10.1200/JCO.2015.63.9898. Epub 2016 Jan 4. PMID: 26729432; PMCID: PMC4872027.

28. Lee N., Xia P., Quivey J.M., Sultanem K. et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002 May 1; 53(1): 12 - 22.

29. Laskar S., Bahl G., Muckaden M., Pai S.K., Gupta T., Banavali S. et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008 Nov 1; 72(3): 728 - 36.

30. Терапевтическая радиология: национальное руководство. Под ред. А.Д. Каприна, Ю.С. Мардынского. М.: ГЭОТАР-Медиа, 2018.

31. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Новик А.В., Романов И.С. Практические рекомендации по лечению злокачественных опухолей головы и шеи//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 71 - 82.

32. Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017; 18: 1221 - 1237.

33. Paris KJ, Spanos WJ Jr, Lindberg RD, et al. Phase I-II study of multiple daily fractions for palliation of advanced head and neck malignancies. Int J Radiat Oncol Biol Phys 1993; 25: 657 - 660.

34. Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim et al. The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer. Cancer Res Treat. 2007 Sep; 39(3): 93 - 98

35. Daniel T.T. Chua, Jonathan S.T. Sham, Gordon K.H. Au, A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma, Oral Oncology, Volume 41, Issue 6, 2005, Pages 589 - 595, ISSN 1368 - 8375, (https://www.sciencedirect.com/science/article/pii/S1368837505000540)

36. Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005). Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23(15), 3562 - 3567.

37. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019; 381: 1124 - 1135.

38. Jacobs, C., Lyman, G., , E. et al (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 10(2), 257 - 263.

39. Grau, J. , Caballero, M., et al (2009). Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Oto-Laryngologica, 129(11), 1294 - 1299.

40. Catimel, G., Verweij, J., Mattijssen, V., et al (1994). Docetaxel (Taxotere(R)): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology, 5(6), 533 - 537.

41. Guardiola, E., Peyrade, F., Chaigneau, L. et al (2004). Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. European Journal of Cancer, 40(14), 2071 - 2076.

42. Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010; 102: 1687 - 91.

43. Zhang L, Zhang Y, Huang P-Y, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008; 61: 33 - 38.

44. Seiwert T.Y., Burtness B., Mehra R. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956 - 965.

45. Chow L.Q., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016; 34: 3838 - 3845.

46. Hsu C., Lee S.H., Ejadi S. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017; 35: 4050 - 4056.

47. Sittel C, Gossmann A, M, M. Superselective embolization as palliative treatment of recurrent hemorrhage in advanced carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2001; 110(12): 1126 - 1128.

48. Clarke P., Radford K., Coffey M., Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130(S2): S176 - 80.

49. Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных.//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 575 - 583

50. Zhao, S. G., Alexander, N. B., Djuric, Z., et al (2015). Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head & Neck, 38(S1), E1086 - E1096.

51. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017 Aug; 24(4): e290 - e31.

52. Samuel S.R., Maiya G.A., Fernandes D.J. et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019.

53. Mustian K.M., Alfano C.M., Heckler C. et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 8.

54. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

55. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 304.

56. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15): 9019.

57. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: a prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016: 38(2): 85 - 94.

58. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

59. He M., Zhang B., Shen N., Wu N., Sun J. A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr 2018; 177(1): 7 - 17.

60. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226 - 33.

61. Avci P., Gupta G.K., Clark J. et al. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med 2013; 46(2): 144 - 51.

62. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

63. Roopashri G. Radiotherapy and chemotherapy induced oral mucositis - prevention and current therapeutic modalities. IJDA 2010; 2: 174 - 9.

64. Сопроводительная терапия в онкологии. Практическое руководство. Под ред. С.Ю. Мооркрафта, Д.Л.Ю. Ли, Д. Каннингэма. Пер. с англ. Под ред. А.Д. Каприна. М.: Гэотар, 2016. 432 с

65. Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009; 19: 29 - 34.

66. Pauloski B.R. Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am 2008; 9: 889 - 928.

67. Arends J. et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. 2021.

68. Duguet A., Bachmann P., Lallemand Y. Summary report of the standards, options and recommendations for malnutrition and nutritional assessment in patients with cancer. Br J Cancer 2003; 89(1): 92 - 7.

69. Снеговой А.В., Лейдерман И.Н., Салтанов А.И., Стрельчук В.Ю. Основные принципы и технологии клинического питания в онкологии: Методическое руководство для врачей. М., 2006.

70. Bozzetti F., Bozzetti V. Efficacy of enteral and parenteral nutrition in cancer patients. Nestle Nutr Workshop Ser Clin Perform Programme 2005; 10: 127 - 39.

71. Roopashri G. Radiotherapy and chemotherapy induced oral mucositis - prevention and current therapeutic modalities. IJDA 2010; 2: 174 - 9.

72. Сопроводительная терапия в онкологии. Практическое руководство. Под ред. С.Ю. Мооркрафта, Д.Л.Ю. Ли, Д. Каннингэма. Пер. с англ. Под ред. А.Д. Каприна. М.: Гэотар, 2016. 432 с.].

73. Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009; 19: 29 - 34. Pauloski B.R. Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am 2008; 9: 889 - 928.

74. Muscaritoli M. et. al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition 40 (2021) 2898 - 2913.

75. Murdoch-Kinch CA, Zwetchkenbaum S. Dental management of the head and neck cancer patient treated with radiation therapy. J Mich Dent Assoc 2011; 93: 28 - 37.

76. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012; 62: 400 - 422.

77. Каприн А.Д., Абузарова Г.Р., с соавт. Новые клинические рекомендации Всемирной организации здравоохранения по терапии онкологической боли у взрослых и подростков. Исследования и практика в медицине. 2021; 8(2): 90 - 108. https://doi.org/10.17709/2410-1893-2021-8-2-9.].

78. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

79. He M., Zhang B., Shen N., Wu N., Sun J. A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr 2018; 177(1): 7 - 17.

80. Self EM, Bumpous J, Ziegler C, Wilson L, Potts K. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Apr; 139(4): 356 - 61. doi: 10.1001/jamaoto.2013.103. PMID: 23599070.

81. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015 Feb 18; 5: 39. doi: 10.3389/fonc.2015.00039. PMID: 25741474; PMCID: PMC4332338.(Self EM, Bumpous J, Ziegler C, Wilson L, Potts K. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Apr; 139(4): 356 - 61. doi: 10.1001/jamaoto.2013.103. PMID: 23599070.).

82. Sittel C, Gossmann A, M, M. Superselective embolization as palliative treatment of recurrent hemorrhage in advanced carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2001; 110(12): 1126 - 1128.

83. Kumra V, Vastola AP, Keiserman S, Lucente FE. Spontaneous tonsillar hemorrhage. Otolaryngol Head Neck Surg. 2001; 124(1): 51 - 52.

84. Smith TP. Embolization in the external carotid artery. J VascIntervRadiol. 2006 Dec; 17(12): 1897 - 912; quiz 1913. doi: 10.1097/01.RVI.0000247301.64269.27. PMID: 17185685.

85. Kumar T, Yadav V, Ravi K, Ramaswamy K, Patel MH, Kothari K. External Carotid Artery Ligation in Squamous Cell Carcinomas of the Oral Cavity and Oropharynx: an Oncological Emergency. Indian J Surg. 2015 Dec; 77 (Suppl 3): 850 - 2. doi: 10.1007/s12262-014-1035-4. Epub2014 Jan 23. PMID: 27011469; PMCID: PMC4775627.

86. Yan L. et al. Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and sys-tematic review//Frontiers in Pharmacology. - 2023. - Т. 13. - С. 1095734.

87. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017; 35: 4050 - 4056.

88. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Systemic therapy/RT comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007; 43: 1399 - 1406.

89. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310 - 1317.

90. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19; 381(12): 1124 - 1135. doi: 10.1056/NEJMoa1905287.

91. He Q, Luo X, Liu L, Zhao C, Li Z, Jin F. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma. BMC Immunol. 2024 May 6; 25(1): 28. doi: 10.1186/s12865-024-00621-3.

92. Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EHW, Tan LLY, Zhang Y, Gong X, Chen Q, Xiang YQ, Chen MY, Guo Y, Lv X, Xia WX, Tang L, Deng X, Guo X, Han F, Mai HQ, Chua MLK, Zhao C. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022 Oct 13; 8(12): 1776 - 85. doi: 10.1001/jamaoncol.2022.4656.

93. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021; 22: 1162 - 1174.

94. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9(5): 188 - 95.

95. Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev, 2021 Nov 16; 11(11): CD012775.

96. Владимирова Л.Ю., Гладков О.А., Королева И.А., Румянцев А.А., Семиглазова Т.Ю., Трякин А.А., Кутукова С.И., Овчинникова Е.Г., Новикова О.Ю., Корниецкая А.Л. Тошнота и рвота. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nausea_vomiting

97. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. v. 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.

98. Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015 Apr; 23(4): 1137 - 43.

99. Mical Paul, Dafna Yahav, Abigail Fraser, Leonard Leibovici. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, Volume 57, Issue 2, February 2006, Pages 176 - 189.

100. Сакаева Д.Д., Борисов К.Е., Булавина И.С., Когония Л.М., Курмуков И.А., Орлова Р.В., Шабаева М.М. Фебрильная нейтропения. Клинические рекомендации RUSSCO, часть 2 https://rosoncoweb.ru/standarts/?chapter=febrile_neutropenia

101. B Vincenzi, A Russo, A Terenzio, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018 Oct; 130: 70 - 77.

102. Devika Remash, David S Prince, Catriona McKenzie, et al. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021 Aug 28; 27(32): 5376 - 5391.

103. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Гепатотоксичность. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=hepatotoxicity

104. Zhujun Mao, Keping Shen, Limin Zhu, et al. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Oncol Res Treat 2019; 42(7 - 8): 405 - 413.

105. Albakri, Aref. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res, 2018, 1(4), doi: 10.15761/TR.1000124.

106. Jasper Tromp, Wouter Ouwerkerk, Dirk J. van Veldhuisen, et al. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol HF. Dec 08, 2021.

107. Kashif Kalam, Thomas H.Marwick. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 2013 Sep; 49(13): 2900 - 9.

108. Виценя М.В., Агеев Ф.Т., Орлова Р.В., Полтавская М.Г., Потиевская В.И. Кардиоваскулярная токсичность. Клинические рекомендации RUSSCO, часть 2 https://rosoncoweb.ru/standarts/?chapter=cardiovascular_toxicity

109. European Society for Medical Oncology. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Annals of Oncology. 2021; 32(2): 157 - 170.

110. Королева И.А., Болотина Л.В., Гладков О.А., Горбунова В.А., Когония Л.М., Круглова Л.С., Орлова Е.В., Орлова Р.В. Дерматологические реакции. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions

111. Emily J Martin, Andrew R Bruggeman, Vinit V Nalawade, et al. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. J Natl Compr Canc Netw 2020 May; 18(5): 569 - 574.

112. M A E de van der Schueren, A Laviano, H Blanchard, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018 May; 29(5): 1141 - 1153.

113. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Обухова О.А., Потапов А.Л., Хотеев А.Ж. Нутритивная поддержка. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nutritional_support

114. Perazella, Mark A. Onco-Nephrology. Renal Toxicities of Chemotherapeutic Agents Clinical Journal of the American Society of Nephrology, 2012 October, 7(10): p 1713 - 1721.

115. Han Li, Jinsheng Xu, Yaling Bai, Shenglei Zhang, Meijuan Cheng, Jingjing Jin. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs, 2021, Volume 39, pages 860 - 870.

116. Songtao Li, Xiuyun He, Linjie Ruan, Ting Ye, Yulong Wen, Zhihua Song, Siying Hu, Yu Chen, Bo Peng, Shijie Li. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11, Published online 2021 Dec 16.

117. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Нефротоксичность. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nephrotoxicity

118. NCCN guidelines. Management of Immunotherapy-Related Toxicities. Version 4, 2021. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

119. Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. Journal for ImmunoTherapy of Cancer, 2018, article number: 103.

120. Guillermo De Velasco, Youjin Je, Dominick , Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi, Toni K. Choueiri. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res, 2017, 5 (4): 312 - 318.

121. Hongchuan Zhang MD, Xuemei Li MD, Xingliang Huang MD, Junfeng Li MD, Hong Ma MD, Rui Zeng MD, Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, Volume 46, Issue 4, August 2021, Pages 927 - 935.

122. Новик А.В., Баллюзек М.Ф., Васильев Д.А. и соавт. Иммуноопосредованные нежелательные явления. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=immunerelated_adverse_events

123. P.Bossi, A.Antonuzzo, N.I.Cherny, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29(4): pages iv126 - iv142.

124. D. E. Peterson, R.-J. Bensadoun, F. Roila. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology 21 (Supplement 5): v261 - v265, 2010.

125. Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю., Корниецкая А.Л., Королева И.А., Нечаева М.Н. и соавт. Мукозиты. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=mucositis

126. Yasuo Ohashi, Yukari Uemura, Yasuhito Fujisaka, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013 Apr; 104(4): 481 - 5.

127. Anat Gafter-Gvili 1, Benaya Rozen-Zvi, Liat Vidal, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013 Jan; 52(1): 18 - 29.

128. Орлова Р.В., Гладков О.А., Кутукова С.И. и соавт. Анемия. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=anemia

129. Fangyuan Zhang, Aomei Shen, Yinghui Jin, Wanmin Qiang. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC Complement Altern Med. 2018; 18: 236.

130. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Потапов А.Л., Хотеев А.Ж. Синдром анорексии-кахексии. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=anorexia-cachexia

131. Marcus Yeow, Shauna Soh, Ryan Yap, Serene Si Ning Goh, Charleen Shanwen Yeo, Zhiwen Joseph Lo. A systematic review and network meta-analysis of randomized controlled trials on choice of central venous access device for delivery of chemotherapy. Journal of Vascular Surgery_ Venous and limphatic disorders. V 10, issue 4, p 1184 - 1191.

132. Исянгулова А.З., Шин А.Р., Петкау В.В. Центральный венозный доступ. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=central_venous_access

133. Firas Y Kreidieh, Hiba A Moukadem, and Nagi S El Saghir Overview, prevention and management of chemotherapy extravasation World J Clin Oncol. 2016 Feb 10; 7(1): 87 - 97.

134. Буйденок Ю.В., Обухова О.А. Экстравазация противоопухолевых препаратов. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=extravasation_antitumor_drugs

135. Margaux Evenepoel, Vincent Haenen, Tom De Baerdemaecker, Mira Meeus, Nele Devoogdt, Lore Dams, Sophie Van Dijck, Elien Van der Gucht, An De Groef. Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis. Pain Symptom Manage, 2022 Mar; 63(3): e317 - e335.

136. Когония Л.М., Новиков Г.А., Орлова Р.В. и соавт. Хронический болевой синдром у взрослых онкологических больных Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=chronic_pain_syndrome

137. S. Rosello, I. Blasco, L. Fabregat, A. Cervantes, K. Jordan. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Annals of Oncology 28 (Supplement 4): iv100 - iv118, 2017.

138. Орлова Р.В., Жабина А.С., Иванова А.К., Наталенко К.Е., Телетаева Г.М. Инфузионные реакции. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=infusion_reactions

139. Khalis Mustafayev, Harrys Torres. Narrative review. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection. Volume 28, Issue 10, October 2022, Pages 1321 - 1327.

140. Феоктистова П.С., Винницкая Е.В., Нурмухаметова Е.А., Тихонов И.Н. Реактивация/обострение хронических вирусных гепатитов во время противоопухолевой терапии. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=chronic_viral_hepatitis

141. Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, Jordi Bruna, Andrea Visentin, Guido Cavaletti, and Chiara Briani. Neurological Complications of Conventional and Novel Anticancer Treatments. Cancers (Basel). 2022 Dec; 14(24): 6088.

142. Латипова Д.Х., Андреев В.В., Маслова Д.А., Новик А.В., Проценко С.А. Неврологические осложнения. Клинические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=neurological_complication

143. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Кутукова С.И., Новик А.В., Романов И.С. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 100 - 119.

144. Министерство здравоохранения Российской Федерации. Анемия при злокачественных новообразованиях: клинические рекомендации (КР624_2). - М., 2024. - 49 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/624_2 (дата обращения: 23.11.2025).

145. Jiang Y, Wei YQ, Luo F, Zou LQ, Liu JY, Peng F, Huang MJ, He QM. Gemcitabine and cisplatin in advanced na-sopharyngeal carcinoma: a pilot study. Cancer Invest. 2005; 23(2): 123 - 8. PMID: 15813504.

146. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005 Apr 6; 97(7): 536 - 9. doi: 10.1093/jnci/dji084. PMID: 15812080.

147. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, Ford J. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007 Jun; 43(9): 1399 - 406. doi: 10.1016/j.ejca.2007.03.022. Epub 2007 Apr 27. PMID: 17467265.

148. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1; 22(1): 69 - 76. doi: 10.1200/JCO.2004.08.021. Epub 2003 Dec 2. PMID: 14657228.

149. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A Phase II trial of docetaxel and cispla-tin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002 Oct; 38(7): 686 - 90. doi: 10.1016/s1368-8375(01)00134-8. PMID: 12167421.

150. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005 Jul; 41(6): 589 - 95. doi: 10.1016/j.oraloncology.2005.01.008. Epub 2005 Apr 14. PMID: 15975521.

151. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combina-tion chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15; 20(6): 1593 - 9. doi: 10.1200/JCO.2002.20.6.1593. PMID: 11896109.